FDA Perspectives on Computer Simulations in the Evaluation of Medical Devices, New Webinar Hosted by Xtalks
Live discussion with FDA and Siemens to provide an overview of the use of individualized computer simulation to predict clinical outcomes in medical device trials
TORONTO, March 15, 2018 (Newswire.com) - The free webinar takes place on Thursday, March 29, 2018, at 1 p.m. EDT, with featured speakers Tina Morrison, Deputy Director of FDA’s Division of Applied Mechanics at the Center for Devices and Radiological Health, and Tom Phillips, Director of Simulation Portfolio Development at Siemens PLM. In addition to a current review of the use of individualized computer simulation in medical device trials, the presentation will also highlight the possibility for in silico clinical trials to be used for evaluating medical products.
FDA acknowledges the benefits to public health provided by modeling and simulation, such as those in the developing area of in silico clinical trials; in other words, the use of individualized computer simulation in the development and/or regulatory evaluation of medical products, medical device or medical interventions (Avicenna Roadmap-2016). FDA advocates for their use as one of many research and product development tools because modeling and simulation play a critical role in organizing diverse data sets, exploring alternate study design strategies, identifying subpopulations for therapy and, in some cases, predicting performance so that safe and effective new therapeutics can advance more efficiently from preclinical studies through clinical trials to market.
FDA routinely advises industry on the use of modeling and simulation to predict clinical outcomes, inform clinical trial designs, support evidence of effectiveness, optimize dosing, identify the most relevant patients to study, predict product safety and evaluate potential adverse event mechanisms. In some cases, in silico clinical trials are used to replace human clinical trials, especially those that are intended to evaluate the risk of drug interactions or where information from a computer-based model can better inform the performance of a medical device as compared to data collection in a human clinical trial. FDA intends to continue advancing these methodologies and techniques from both a science and regulatory perspective to best take advantage of the benefits for continued product innovation and more rapid introduction of life-saving technology to U.S. patients.
For more information about this complimentary webinar, visit FDA Perspectives on Computer Simulations in the Evaluation of Medical Devices.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical and biotech companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/sponsorship.ashx.
Contact:
Nima Rajan
Tel: +1 (416) 977-6555 ext 352
Email: nrajan@xtalks.com
Source: Xtalks
Related Media
